AstraZeneca's diabetes drug Farxiga cuts risk of CV death or worsening of heart failure by 26% in landmark study
About two weeks after AstraZeneca’s $AZN unveiled its diabetes treatment Farxiga cut the risk of CV death or the worsening of heart failure in patients with heart disease, in a landmark trial — over the weekend the British drugmaker presented detailed data at the European Society of Cardiology (ESC) Congress in Paris.
The results emanated from the 4,744-patient DAPA-HF trial, which tested Farxiga in patients with reduced ejection fraction (HFrEF) — in which the heart muscle is not able to contract amply and, therefore, expels less oxygen-rich blood into the body — on standard of care treatment, including those with and without type-II diabetes.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.